Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
AlloVir
company
About
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $126.60M
- Industries
- Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.The company was founded in 2013 and headquartered in Houston, Texas.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$126.60M
AlloVir has raised a total of
$126.60M
in funding over 2 rounds. Their latest funding was raised on
Jul 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 27, 2022 | Post-IPO Equity | $126.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
AlloVir is funded by 1 investors.
Kite Pharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
